CA3073669A1 - Compositions and methods for treating cancer - Google Patents
Compositions and methods for treating cancer Download PDFInfo
- Publication number
- CA3073669A1 CA3073669A1 CA3073669A CA3073669A CA3073669A1 CA 3073669 A1 CA3073669 A1 CA 3073669A1 CA 3073669 A CA3073669 A CA 3073669A CA 3073669 A CA3073669 A CA 3073669A CA 3073669 A1 CA3073669 A1 CA 3073669A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- onecut2
- agent
- day
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548879P | 2017-08-22 | 2017-08-22 | |
| US62/548,879 | 2017-08-22 | ||
| PCT/US2018/047569 WO2019040647A1 (en) | 2017-08-22 | 2018-08-22 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3073669A1 true CA3073669A1 (en) | 2019-02-28 |
Family
ID=65440144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073669A Pending CA3073669A1 (en) | 2017-08-22 | 2018-08-22 | Compositions and methods for treating cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11529338B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3672582B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7293194B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111182894A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018321950A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3073669A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272782A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019040647A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3468546A4 (en) | 2016-06-09 | 2020-04-01 | Cedars-Sinai Medical Center | COMPOSITIONS AND METHODS FOR TREATING CANCER |
| WO2021071812A1 (en) * | 2019-10-07 | 2021-04-15 | D.E Shaw Research, Llc | Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers |
| PL447378A1 (pl) * | 2023-12-29 | 2025-06-30 | Uniwersytet Medyczny W Lublinie | Zastosowanie lepidylin w leczeniu nowotworu układu nerwowego. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6048877A (en) * | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
| US6218367B1 (en) | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7892740B2 (en) | 2006-01-19 | 2011-02-22 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
| AU2009212543B2 (en) | 2008-02-01 | 2015-07-09 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| US20140056807A1 (en) | 2012-08-23 | 2014-02-27 | Cedars-Sinai Medical Center | Large oncosomes in human tumors and in circulation in patients with cancer |
| EP2968371A4 (en) * | 2013-03-12 | 2017-04-12 | The Board of Trustees of the Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| EP2986326B1 (en) | 2013-04-15 | 2018-09-05 | Cedars-Sinai Medical Center | Methods for detecting cancer metastasis |
| WO2015166295A1 (en) * | 2014-04-29 | 2015-11-05 | Ecole Normale Superieure De Lyon | Azoaryls as reversibly modulatable tubulin inhibitors |
| JP2017518312A (ja) * | 2014-06-05 | 2017-07-06 | ユニバーシティ・オブ・カンザス | マルメリン類似体および癌治療における使用方法 |
| WO2015197909A1 (en) | 2014-06-27 | 2015-12-30 | Fermion Oy | Process for the preparation of a crystalline polymorph of 2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (benserazide) hydrochloride |
| CA2996426A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| EP3468546A4 (en) | 2016-06-09 | 2020-04-01 | Cedars-Sinai Medical Center | COMPOSITIONS AND METHODS FOR TREATING CANCER |
-
2018
- 2018-08-22 CA CA3073669A patent/CA3073669A1/en active Pending
- 2018-08-22 CN CN201880061797.2A patent/CN111182894A/zh active Pending
- 2018-08-22 WO PCT/US2018/047569 patent/WO2019040647A1/en not_active Ceased
- 2018-08-22 AU AU2018321950A patent/AU2018321950A1/en not_active Abandoned
- 2018-08-22 EP EP18848878.7A patent/EP3672582B1/en active Active
- 2018-08-22 JP JP2020510543A patent/JP7293194B2/ja active Active
- 2018-08-22 US US16/640,902 patent/US11529338B2/en active Active
-
2020
- 2020-02-19 IL IL272782A patent/IL272782A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018321950A1 (en) | 2020-03-19 |
| JP2020531495A (ja) | 2020-11-05 |
| EP3672582A1 (en) | 2020-07-01 |
| US20200188373A1 (en) | 2020-06-18 |
| WO2019040647A1 (en) | 2019-02-28 |
| JP7293194B2 (ja) | 2023-06-19 |
| EP3672582B1 (en) | 2026-04-15 |
| EP3672582A4 (en) | 2021-05-05 |
| CN111182894A (zh) | 2020-05-19 |
| IL272782A (en) | 2020-04-30 |
| US11529338B2 (en) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421185B2 (en) | Compositions and methods for treating cancer | |
| JP7582694B2 (ja) | Ｍｅｋ阻害剤及びその治療的使用 | |
| RU2701193C2 (ru) | Арилхиназолины | |
| CN112225724B (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
| US20200325115A1 (en) | Heterocyclic compounds as immunomodulators | |
| BR112020004559A2 (pt) | inibidores de enpp1 e seus usos para o tratamento de câncer | |
| CN112654622B (zh) | 并环化合物、其制备方法及用途 | |
| CN102317293A (zh) | Raf抑制剂及其用途 | |
| EA032070B1 (ru) | Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания | |
| BR112014001600B1 (pt) | Composto inibidor do trajeto de sinalização notch, seus usos, e composição farmacêutica | |
| US11529338B2 (en) | Compositions and methods for treating cancer | |
| JP7611934B2 (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| CA2927830A1 (en) | Quinazolinone and isoquinolinone derivative | |
| EP4143191A2 (en) | Bicyclic kinase inhibitors and uses thereof | |
| CN112055714B (zh) | 二甲基氧膦类化合物 | |
| US20230056497A1 (en) | CD206 Modulators Their Use and Methods for Preparation | |
| WO2022242725A1 (zh) | 一类新型蛋白降解剂及其应用 | |
| WO2022089389A1 (zh) | 杂环化合物及其制备方法、药物组合物和应用 | |
| CN115724844A (zh) | 一种具有抗肿瘤活性的杂环化合物及其用途 | |
| CN115304598B (zh) | 一种杂环类化合物及其制备方法和用途 | |
| US20250152751A1 (en) | Red-shifted fluorophores and methods of using the same | |
| US20160250190A1 (en) | N-methyl pyrazoloanthrone for treatment of cancer | |
| CN115215883A (zh) | Usp7抑制剂 | |
| US20230026271A1 (en) | Piperazine Compounds for Inhibiting CPS1 | |
| RU2812929C1 (ru) | Ингибиторы mek и их терапевтическое применение |